Related Experiment Videos
Chemotherapy for renal cell carcinoma.
1Department of Genitourinary Medical Oncology, University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Seminars in Oncology
|April 18, 2000
Summary
Renal cell carcinoma (RCC) shows high resistance to chemotherapy, with no standard treatment for metastatic disease. Investigational therapies are recommended for advanced RCC due to limited available options.
Area of Science:
- Oncology
- Medical Research
Background:
- Renal cell carcinoma (RCC) is a complex malignancy.
- Current systemic chemotherapy options for metastatic RCC are limited and often ineffective.
Purpose of the Study:
- To review the limited experience with chemotherapy in treating advanced or metastatic renal cell carcinoma.
- To highlight the need for novel therapeutic strategies in RCC management.
Main Methods:
- Literature review of chemotherapy efficacy in renal cell carcinoma.
- Analysis of treatment outcomes for advanced and metastatic RCC.
Main Results:
- Systemic chemotherapy agents are not considered standard for metastatic renal cell carcinoma.
- Limited therapeutic options are currently available for advanced RCC patients.
Conclusions:
- Patients with advanced or metastatic renal cell carcinoma should be offered investigational and experimental treatment options.
- Further research into novel therapies is crucial for improving outcomes in renal cell carcinoma.